Creative Planning’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Creative Planning’s Portfolio ICPT Stock Details ICPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-100	Closed	-$1K	–	4971
2016 Q4	$1K	Buy	+100	New	+$11.9K	﹤0.01%	4522
2014 Q2	–	Sell	-900	Closed	-$7K	–	4006
2014 Q1	$7K	Buy	+900	New	+$304K	﹤0.01%	2954

Other funds holding ICPT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SCM

Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Creative Planning's ICPT Position: Q4 2019 in Review

Creative Planning sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q4 2019, closing a stake of 10,905 shares — an estimated $724K sold.

Creative Planning first reported a position in ICPT in Q3 2014 and held it in 16 quarters. The position peaked at $3.71M in Q1 2019. 215 funds tracked by Wall St. Rank hold ICPT as of Q4 2019.

Creative Planning reported no remaining Intercept Pharmaceuticals, Inc. position as of Q4 2019 after selling out during the quarter.
Creative Planning sold 10,905 Intercept Pharmaceuticals, Inc. shares in Q4 2019, an estimated $724K.
Creative Planning first reported a position in Intercept Pharmaceuticals, Inc. in Q3 2014 and held it in 16 quarters.
Creative Planning's Intercept Pharmaceuticals, Inc. position peaked at $3.71M in Q1 2019.
215 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q4 2019.

Based on Creative Planning's 13F filing for Q4 2019, filed 30 Jan 2020.